180 related articles for article (PubMed ID: 21599630)
1. Novel approaches to target pancreatic cancer.
Porzner M; Seufferlein T
Curr Cancer Drug Targets; 2011 Jul; 11(6):698-713. PubMed ID: 21599630
[TBL] [Abstract][Full Text] [Related]
2. [Recent update of molecular targeted therapy in pancreatic cancer].
Cho JH
Korean J Gastroenterol; 2013 Mar; 61(3):147-54. PubMed ID: 23575233
[TBL] [Abstract][Full Text] [Related]
3. Molecular-targeted agents in pancreatic cancer.
Saad ED; Hoff PM
Cancer Control; 2004; 11(1):32-8. PubMed ID: 14749621
[TBL] [Abstract][Full Text] [Related]
4. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers.
Diaz-Rubio E
Oncologist; 2004; 9(3):282-94. PubMed ID: 15169983
[TBL] [Abstract][Full Text] [Related]
5. Targeting EGFR in pancreatic cancer treatment.
Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
[TBL] [Abstract][Full Text] [Related]
6. Molecular and genetic bases of pancreatic cancer.
Vaccaro V; Gelibter A; Bria E; Iapicca P; Cappello P; Di Modugno F; Pino MS; Nuzzo C; Cognetti F; Novelli F; Nistico P; Milella M
Curr Drug Targets; 2012 Jun; 13(6):731-43. PubMed ID: 22458519
[TBL] [Abstract][Full Text] [Related]
7. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
[TBL] [Abstract][Full Text] [Related]
8. Target therapies in pancreatic carcinoma.
Silvestris N; Gnoni A; Brunetti AE; Vincenti L; Santini D; Tonini G; Merchionne F; Maiello E; Lorusso V; Nardulli P; Azzariti A; Reni M
Curr Med Chem; 2014; 21(8):948-65. PubMed ID: 23992319
[TBL] [Abstract][Full Text] [Related]
9. State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now?
Balsano R; Tommasi C; Garajova I
Anticancer Res; 2019 Jul; 39(7):3405-3412. PubMed ID: 31262862
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.
Caparello C; Meijer LL; Garajova I; Falcone A; Le Large TY; Funel N; Kazemier G; Peters GJ; Vasile E; Giovannetti E
World J Gastroenterol; 2016 Aug; 22(31):6987-7005. PubMed ID: 27610011
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer: molecular pathogenesis and new therapeutic targets.
Wong HH; Lemoine NR
Nat Rev Gastroenterol Hepatol; 2009 Jul; 6(7):412-22. PubMed ID: 19506583
[TBL] [Abstract][Full Text] [Related]
12. A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer.
Gilmour AM; Abdulkhalek S; Cheng TS; Alghamdi F; Jayanth P; O'Shea LK; Geen O; Arvizu LA; Szewczuk MR
Cell Signal; 2013 Dec; 25(12):2587-603. PubMed ID: 23993964
[TBL] [Abstract][Full Text] [Related]
13. HER family inhibitors in pancreatic cancer: current status and future directions.
Berz D; Miner T; McCormack E; Safran H
Expert Opin Ther Targets; 2007 Mar; 11(3):337-47. PubMed ID: 17298292
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review.
Arnold D; Peinert S; Voigt W; Schmoll HJ
Oncologist; 2006 Jun; 11(6):602-11. PubMed ID: 16794239
[TBL] [Abstract][Full Text] [Related]
15. New target therapies in advanced pancreatic cancer.
Cascinu S; Verdecchia L; Valeri N; Berardi R; Scartozzi M
Ann Oncol; 2006 May; 17 Suppl 5():v148-52. PubMed ID: 16807445
[TBL] [Abstract][Full Text] [Related]
16. Drug development in pancreatic cancer: finally, biology begets therapy.
Cohen SJ; Meropol NJ
Int J Gastrointest Cancer; 2002; 32(2-3):91-106. PubMed ID: 12794245
[TBL] [Abstract][Full Text] [Related]
17. Molecularly targeted therapy for gastrointestinal cancer.
Wiedmann MW; Caca K
Curr Cancer Drug Targets; 2005 May; 5(3):171-93. PubMed ID: 15892618
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer: from molecular signature to target therapy.
Longo R; Cacciamani F; Naso G; Gasparini G
Crit Rev Oncol Hematol; 2008 Dec; 68(3):197-211. PubMed ID: 18436450
[TBL] [Abstract][Full Text] [Related]
19. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
20. Advanced or metastatic pancreatic cancer: molecular targeted therapies.
Bayraktar S; Rocha-Lima CM
Mt Sinai J Med; 2010; 77(6):606-19. PubMed ID: 21105124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
